THU0163 Early Response as A Predictor of Long-Term Clinical Response in DMARD-Naïve Patients with Severe, Active and Progressive RA Treated with Certolizumab Pegol plus Optimized MTX versus Optimized MTX Alone

X Mariette,D Van Der Heijde,M Weinblatt,B Vanlunen,V.P Bykerk,G.-R Burmester,R Van Vollenhoven,D Furst,P Emery,C Arendt,C Bingham

doi:10.1136/annrheumdis-2016-eular.1471

THU0163 Early Response as A Predictor of Long-Term Clinical Response in DMARD-Naïve Patients with Severe, Active and Progressive RA Treated with Certolizumab Pegol plus Optimized MTX versus Optimized MTX Alone

X Mariette, D Van Der Heijde + Show 9 more

https://doi.org/10.1136/annrheumdis-2016-eular.1471

Copy DOI

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2016

Affiliation: University of Paris-Sud, Institut Polytechnique de Paris, Leiden University Medical Center, Brigham and Women's Hospital, UCB Pharma (United States), Cornell University, University of Leeds, UCB Pharma (Belgium), Johns Hopkins University

#UCB Pharma #Severe RA + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundC-EARLY (NCT01519791) assessed the efficacy and safety of certolizumab pegol (CZP)+optimized MTX vs placebo (PBO)+optimized MTX in inducing and maintaining a sustained clinical response, and inhibiting radiographic damage, in DMARD-naïve...

Full Text